Vigonvita Life Sciences Co., Ltd. (VIGONVITA-B) filed its Monthly Return for Equity Issuer for the period ended 30 September 2026, confirming that both its authorised and issued share capital remained unchanged during the month and that the company continued to meet Hong Kong’s minimum public‐float requirement.

Authorised / Registered Capital • Ordinary H shares listed on the Stock Exchange: 166.90 million shares at RMB 1 par value, representing RMB 166.90 million in authorised capital. • Unlisted ordinary shares: 0.70 million shares at RMB 1 par value, equal to RMB 0.70 million. • Total authorised / registered share capital closed the month at RMB 167.60 million, unchanged from August 2026.

Issued Shares and Treasury Position • Listed H shares in issue: 166.90 million; no treasury shares were held. • Unlisted shares in issue: 0.70 million. • No issuance, cancellation, or repurchase of shares occurred during September, leaving the total issued share count steady at 167.60 million.

Public Float The company affirmed compliance with the Main Board’s minimum public‐float threshold of 25 percent for its H-share class as at 30 September 2026.

Capital Instruments The filing states there were no outstanding share options, warrants, convertibles, or other agreements that could dilute the current share base.

Corporate Governance Confirmation Board secretary Guo Ting certified that all regulatory obligations relating to share capital during the month were met, with no unreported securities issues or treasury share transactions.

Overall, VIGONVITA-B’s September return indicates a stable capital structure with no equity movements and full adherence to Hong Kong listing requirements.